HLA B7 anticorps

N° du produit ABIN1027673

5+ publications sont disponibles pour ce produit. L’anticorps anti-HLA B7 Monoclonal produit chez le Souris a été validé pour FACS. Il convient pour la détection de HLA B7 dans des échantillons provenant de Humain et Non-Human Primate. }

Aperçu rapide pour HLA B7 anticorps (ABIN1027673)

Antigène: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Reactivité: Humain, Non-Human Primate

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp HLA B7 est non-conjugé

Application: Flow Cytometry (FACS)

Clone: BB7-1

Détail du produit anti-HLA B7 anticorps

Fonction: Anti-HLA-B7 Purified

Specificité: The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.

Réactivité croisée (Details): Human, Non-Human Primates

Purification: Purified by protein-A affinity chromatography.

Pureté: > 95 % (by SDS-PAGE)

Immunogène: Papain solubilised HLA-A2, B7

Isotype: IgG1

Information d'application

Indications d'application: Flow cytometry: Recommended dilution: 1-4 μg/mL.

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze.

Stock: 4 °C

Stockage commentaire: Store at 2-8°C. Do not freeze.

Références pour anticorps anti-HLA B7 (ABIN1027673)

Cortez-Gonzalez, Sidney, Adotevi, Sette, Millard, Lemonnier, Langlade-Demoyen, Zanetti: "Immunogenic HLA-B7-restricted peptides of hTRT." dans: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).

de la Salle, Saulquin, Mansour, Klayme, Fricker, Zimmer, Cazenave, Hanau, Bonneville, Houssaint, Lefranc, Naman: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." dans: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).

Rini, Selk, Vogelzang: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).

Trapani, Vaughan, Tait, McKenzie: "Immunoradiometric assay for the rapid detection of HLA-B27." dans: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).

Storkus, Alexander, Payne, Dawson, Cresswell: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).

Détails sur HLA B7

Antigène: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Autre désignation: HLA-B7

Sujet: HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.

Pathways: Human Leukocyte Antigen (HLA) in Adaptive Immune Response